AI assistant
Qualigen Therapeutics, Inc. — Director's Dealing 2017
Oct 27, 2017
35251_dirs_2017-10-27_16595564-5762-4df8-8790-31dc2f601780.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RITTER PHARMACEUTICALS INC (RTTR)
CIK: 0001460702
Period of Report: 2017-10-03
Reporting Person: Ritter Andrew J (President, 10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-10-03 | Common Stock | P | 187500 | — | Acquired | 1004772 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-10-03 | Warrants (Right to Buy) | $.44 | P | 187500 | Acquired | 2022-10-03 | Common Stock (187500) | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 6250 | Direct |
Footnotes
F1: Stonehenge Partners LLC ("Stonehenge") purchased 187,500 Class A Units of the Issuer, consisting of 187,500 shares of common stock and warrants to purchase 187,500 shares of common stock, in the Issuer's October 2017 public offering at the public offering price of $0.40 per Class A Unit. The shares of common stock and warrants that are part of the Class A Units sold to Stonehenge in the public offering were immediately separable and were issued separately in the offering.
F2: As a managing partner of Stonehenge, the Reporting Person may be deemed the beneficial owner of these securities. The Reporting Person expressly disclaims beneficial ownership over these securities except to the extent of his pecuniary interest therein.